The intestinal bile acid carrier ASBT (SLC10A2), the hepatic bile acid carrier NTCP (SLC10A1),and the steroid sulfate carrier SOAT (SLC10A6), allmembers of the solute carrier family SLC10, are established drug targets.The ASBT inhibitors odevixibat, maralixibat, and elobixibat are usedto treat intrahepatic cholestasis, cholestatic pruritus, and obstipation.The peptide drug bulevirtide blocks binding of the hepatitis B andD viruses to NTCP and thereby inhibits the virus’s entry intohepatocytes. This evidence concerns the gene SLC10A6 and intrahepatic cholestasis.